The Japanese research institute RIKEN has come full circle in a way on the STAP cell scandal. Note that the STAP papers included not only authors from RIKEN, but also from Brigham and Women’s Hospital/Harvard Medical School.
With its final report released today (also a powerpoint of images were released including the one showing a figure posted here of reportedly made up data published in a STAP paper), RIKEN seems to now have handled this complicated mess in a relatively rigorous, scientific manner that paves the way for moving on from it.
What would you have done in RIKEN’s shoes? It’s not a pleasant thing to contemplate.
As a research institution, what do you do if a potential major scientific scandal is cropping up under your roof? It’s unpredictable and dangerous and couldn’t have come at a worse time for RIKEN. So how do you handle it? What would you have done?
RIKEN was faced with this kind of unpleasant reality early this year. A very high moment for RIKEN with the publication of two seemingly groundbreaking Nature papers including numerous RIKEN authors quickly headed the other direction and began unraveling.
By February, only weeks after the STAP cell papers were published supposedly reporting the creation of power stem cells called “STAP cells”, there were signs that the research was plagued with profound problems including signs of potential misconduct.
At that point in February and March, what should the leaders at RIKEN do/have done? I’m sure they were asking themselves this tough question.
There have been ups and downs as to how RIKEN has handled STAP, but in the new report there are indications of a sober, objective and more thorough approach to STAP. I think this is a positive, constructive step even if the conclusions are negative and sad.
Dennis Normile has a nice summary over at Science News of the RIKEN report:
“The committee determined that 3 supposed STAP stem cell lines were actually likely to be 3 previously existing embryonic stem (ES) cell lines. “It is unlikely that there was accidental contamination by three different ES cells, and it is suspected that the contamination may have occurred artificially…”
This new RIKEN report on STAP has concluded that what were claimed to be STAP cells were almost certainly embryonic stem cells (ESCs) instead. It cannot be sure if the ESCs were intentionally and fraudulently used, but it says that is probable. If it was done on purpose RIKEN also cannot be sure who did it.
The report concludes that STAP first author Haruko Obokata, who RIKEN earlier had determined committed certain STAP-related misconduct, committed additional misconduct over certain data, but the report also lays some of the blame for STAP to lack of proper supervision by senior STAP authors Yoshiki Sasai, Teruhiko Wakayama, and Hitoshi Niwa. One remaining thing we do not know is what this report means for Wakayama or Niwa, the latter still being at RIKEN.
So what does all of this mean and where do things go from here?
While there is still some more to resolve on the Japan side of STAP, my impression is that this report along with Obokata’s resignation allows for RIKEN to really begin to move on from STAP.
Normile’s article concludes pointing towards where the STAP-related focus may turn next:
One of the papers’ co-authors has been beyond the reach of RIKEN investigators: Charles Vacanti, a tissue engineer at Brigham and Women’s Hospital in Boston, an affiliate of Harvard Medical School. Obokata initiated her work on STAP cells while a post-doc in Vacanti’s lab. Mutsuhiro Arinobu, a RIKEN executive director, said that although they have been in contact with Harvard, input from Vacanti “is not included in this investigation.”
Harvard and Brigham and Women’s Hospital may or may not be conducting STAP investigations of their own. However, certainly at this point relatively speaking key unanswered questions remain on the Harvard side of STAP.